|Bid||98.34 x 1000|
|Ask||98.40 x 800|
|Day's range||97.16 - 100.49|
|52-week range||88.25 - 308.00|
|Beta (5Y monthly)||0.38|
|PE ratio (TTM)||N/A|
|Earnings date||22 Feb 2022 - 28 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||163.23|
Teladoc Health (NYSE: TDOC) shareholders lost ground to the market last month as their stock dove 32% compared to a 0.8% decline in the S&P 500. According to data from S&P Global Market Intelligence, the slump helped push shares down over 50% so far in 2021 compared to an over 22% spike in the wider market. Investors sold shares off during last month's move against high-growth tech stocks, too.
ARK Invest's chief stock picker has bought and sold the wrong stocks in 2021, but it's hard to bet against a recovery next year.
Shares of Teladoc Health (NYSE: TDOC) were tumbling 12.1% this week as of the market close on Thursday, according to data from S&P Global Market Intelligence. The decline came as the stock market fell over the past few days. One key reason behind the stock market's decline was concern about the emergence of the omicron variant.